RxDoctor Payments Data

Holly Pierce

Adult Health · Nashville, TNNPI 1073797502

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Boston Scientific at 29.0% of the total.

$3,440in general payments, 2019–2025

Across 132 payments — averaging $26.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$999
  • Amgen$921
  • Novartis$558
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$382
  • Esperion Therapeutics, Inc.$217
  • Boehringer Ingelheim$107
  • plus $256 from 7 others

What the payments were for

  • Food & beverage$3,440100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,440 in reported general payments places this provider in the 80th percentile of 352 adult health providers in Tennessee.

See all adult health providers in Tennessee

Medicare billing

Part B allowed, 2024
$71,638
Medicare patients
543
Services billed
752

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban154$236,037
Repatha SureclickEvolocumab162$155,220
Praluent PenAlirocumab59$40,200
XareltoRivaroxaban24$39,372
EntrestoSacubitril/Valsartan14$13,448
JardianceEmpagliflozin12$9,151
Atorvastatin Calcium333$4,059
VascepaIcosapent Ethyl11$3,876
Rosuvastatin Calcium272$3,775
Metoprolol Succinate169$2,311
Losartan Potassium192$2,097
Prasugrel Hcl17$1,823
Amlodipine Besylate278$1,805
Carvedilol190$1,512
Flecainide Acetate22$1,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$558$13,44814 claims
Boehringer IngelheimJardiance$107$9,15112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 352 adult health providers in Tennessee.

Other adult health in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →